Date: 2017-06-26
Type of information: Private placement
Company: Sangamo Therapeutics (USA - CA)
Investors:
Amount: $83.4 million
Funding type: private placement
Planned used:
- Sangamo intends to use the proceeds from this offering for working capital and other general corporate purposes, including support for the continuing research and development of its genomic therapy product candidates and research programs, clinical trials, commercialization activities, business development activities and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to Sangamo's business.
Others:
- • On June 26, 2017, Sangamo Therapeutics announced the closing of its public offering of 10,000,000 shares of common stock at a price to the public of $7.25 per share. In addition, the underwriters of the announced public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock. Including this option exercise, the total gross proceeds from the offering of an aggregate of 11,500,000 shares at a price to the public of $7.25 per share will be approximately $83.4 million, before deducting the underwriting discounts and commissions and other offering expenses.
- • On June 21, 2017, Sangamo Therapeutics announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $7.25 per share. All of the shares are being sold by Sangamo. The gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $72.5 million. In connection with this offering, Sangamo granted to the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock.
- • On June 20, 2017, Sangamo Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Sangamo. Sangamo intends to grant the underwriters a 30 day option to purchase up to 15% of the number of shares of common stock to be sold in the offering. Sangamo intends to use the proceeds from this offering for working capital and other general corporate purposes, including support for the continuing research and development of its genomic therapy product candidates and research programs, clinical trials, commercialization activities, business development activities and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to Sangamo's business.
- Cowen and Company, LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.
Therapeutic area: Rare diseases - Genetic diseases
Is general: Yes
